Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seems a little early in the day for something like that. Though I know what you mean. These are rough times to get through.
I wish pot was legal in my state by now. Hmm. maybe I could try to get a prescription for "stress"?? :)
Nah. Guess I'll just go have breakfast and listen to "Montana". That usually cheers me up...
It was a safety study trial, which they passed. They didn't have to report any observations about effectiveness. That's what the next study is for, that they are now cleared to proceed on.
This is like goro in the early days before the official drill results were in but a geologist remarked that there were indications of a massive vein of mineralization. People had an opportunity to buy in low on what was technically a "rumor" but speculators often buy in on rumors that are weaker than that. Maybe it would't "pan out", most didn't, but in the case of goro, it did indeed prove to be a bonanza grade gold find. As it turned out, I bailed a little too early, but I did make some money. The other thing about goro was that after DD I had confidence in the management unlike most of the hundred exploratory startups staking out new claims everywhere. Also similar to the plethora of small biotechs today.
My arm is still sore from patting myself on the back for buying premarket yesterday at 8.50 Now my leg is sore from kicking myself for not waiting. :)
I don't know, if it falls through 6.00 I will probably start buying again, but who knows how low the forces in play can take it.
Thinking about the theories here. I just got up so haven't read all the posts ahead, someone may have thought of this already:
There is a third possibility - softening up the target with repeated bombing runs in preparation for a future hostile takeover.
I've watched it happen on a scale larger than this. There are high stakes here.
So much for all the hubris earlier.
I agree with the guy that said not to go around poking bears.
oops sorry this was supposed to be a new message. not a reply to you.
I can edit but not delete a message apparently. Tired from reading the hundreds of posts here today...
I think it just hit the 0.10 threshold on the convertbles, pause could be creditors waiting to decide if they really want to start a death spiral at this point. - read the 10k
Well, the barrage of selling stopped. There's that.
Odd that it stopped all at once, from 100k / day to zilch.
Not sure what that means...
what do the "false alarms" pertain to?
Phase 2 Trials Starting
https://clinicaltrials.gov/ct2/show/NCT02593227?term=TapImmune&rank=1
Um, I didn't read it because my security software has that flagged as a virus / malware site.
I also heard via other posts that the conservative gov cut back on agencies pretty much across the board. That tends to produce a subtle work slowdown effect. I noticed that happening in a dept. at a co. I used to work, so, such potential tactics are not limited to government workers/unions. (Notwithstanding, it also tends to work.) Also, a good part of vacations are taken during the summer...
I'm also invested in a medical device co. and HC is also way late on processing their application, which has also slammed the sp on that. Apart from tormenting investers, the end result is that sick people have to wait longer for a cure. Some of them will run out of time.
What's exasperating is the lack of transparency with this agency. It's not like it's the the cia, (or whatever Canadian equivalent). Canadian citizens at least should be able to see what HC is working on, progress, work pipeline, like tracking a package at the post office...
HC explains reasons for it's lag of inspections.
http://blog.liftcannabis.ca/2015/01/12/health-canada-refines-the-mmpr-approval-process/
I think Tweed should look at buying Supreme not Organigram because:
1. Bargain price now due to being inspection ready for months due HC secrecy and inexplicable slowing to snail's pace about scheduling LP inspections. Supremes application is long standing but it now appears they made it in under the wire. Inspection for License to Grow they are sure to pass, coming any day now... :)
2. Beautiful huge grow-ready high-tech green house facility comparable to Niagra on the Lake
3. $2 / gram cited aimed at low-cost market sector.
4. No legal problems.
5. As a Tweed subsidiary, Supreme wouldn't have to worry about enduring additional HC hurdles and ensuing long delay for License to Sell.
Where did you see that?
WHITEFISH, MT / ACCESSWIRE / May 5, 2015 /" The final arguments are being given this week in a court challenge of the Canadian federal government's move to ban home growing of medical marijuana by doctor-approved users. If home-grow advocates succeed, the ruling could serve a big blow to the newly implemented Marihuana for Medical Purposes Regulations ("MMPR") that aimed to force all patients to buy from approved commercial producers.
The uncertainty surrounding the MMPR program has led Health Canada - the government's regulatory body - to delay approvals for many aspiring licensed producers. While some companies have already been approved, including Tweed Marijuana Inc. (TWMJF) and OrganiGram Holdings Inc. (OGI.V) (OGRMF), others have been forced into a holding pattern."
re: apeks supercritical
too bad it's a private co. - can't buy stock in it.
Couldn't it be cloned from cuttings?
re: "...Yet another tax proposal by Davis, LB201, would institute a tax on the rare earth mineral Niobium..."
Rare earth mineral? Haven't heard that term before.
Niobium isn't even a rare earth element.
Shows how much they know.
Unquestionably, this has been a bonanza for short sellers. Now, the hit pieces are finally starting to disappear from the financial media. The following seeking alpha blog piece appears no longer active. This link is from a cached page, not sure how long it will keep working. The first lengthy part basically re-iterates a lot of the short-seller thesis points we have all heard - even uses the term "bagholder" (how nice).
Longs may want to skip ahead. The refuting comments way down at the end are interesting.
http://98.139.236.92/search/srpcache?p=ibio+caliper+emergency+use+license&type=W3i_SP%2C204%2C0_0%2CStartPage%2C20141041%2C20029%2C0%2C25%2C3662&hsimp=yhs-syctransfer&hspart=w3i&ei=UTF-8&u=http://cc.bingj.com/cache.aspx?q=ibio+caliper+emergency+use+license&d=4638441525478310&mkt=en-US&setlang=en-US&w=thkkKnpnyGY9UZiINRzNax8yijWDHAhR&icp=1&.intl=us&sig=2HkmOUDJ8JX8Uq_5X_0Z2w--
Sometimes when there's equity financing, private placements and so forth, it will tend to set a stock's perceived value for a while.
Sometimes...
From the last 10-K:
"18. Subsequent Events
On August 25, 2014, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company (referred to below as “Aspire Capital”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $10.0 million of shares of the Company’s common stock over the approximately 24-month term of the purchase agreement. In consideration for entering into the purchase agreement, following the approval of the issuance of the shares by NYSE MKT, Aspire Capital received 681,818 shares of the Company’s common stock as a commitment fee. In addition, on September 19, 2014 following approval of the issuance of the shares by NYSE MKT, Aspire Capital purchased 1,136,354 shares of common stock for $500,000 pursuant to the terms of the purchase agreement.
Concurrently with entering into the purchase agreement, the Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements as permissible and necessary to register under the Securities Act of 1933, as amended, the sale of shares of the Company’s common stock that have been and may be issued to Aspire Capital under the purchase agreement. After the Securities and Exchange Commission has declared effective the registration statement, on any trading day on which the closing sale price of the Company’s common stock exceeds $0.44 (the closing sale price of the Company’s shares on the business day before the Company entered into the purchase agreement with Aspire Capital), the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice, directing Aspire Capital (as principal) to purchase up to 150,000 shares of common stock per trading day, provided that the aggregate price of such purchase shall not exceed $500,000 per trading day, up to an additional $9.5 million of common stock in the aggregate at a per share price equal to the lesser of the lowest sale price of common stock on the purchase date, or the arithmetic average of the three lowest closing sale prices of common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date.
In addition, on any date on which the Company submits a purchase notice to Aspire Capital in an amount equal to 150,000 shares of common stock and the closing sale price of common stock is equal to or greater than $0.44, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price (“VWAP”) purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the NYSE MTK on the next trading day, subject to a maximum number of shares that the Company may determine, and a minimum trading price which is equal to the greater of (a) 80% of the closing price of common stock on the business day immediately preceding the date of the VWAP purchase, or (b) such higher price as set forth by the Company in the notice for the VWAP purchase. The purchase price per share pursuant to such VWAP purchase notice shall be the lower of (i) the closing sale price on the date of sale and (ii) 97% of the volume-weighted average price for common stock traded on the NYSE MKT on (i) the date of the VWAP purchase if the aggregate stock to be purchased on that date does not exceed the volume maximum stated in the Company’s notice for the VWAP purchase, or (ii) the portion of such business day until such time as aggregate stock to be purchased will equal the volume maximum stated in the Company’s notice or the time at which the sale of the stock falls below the minimum trading price described above.
The purchase agreement provides that the Company and Aspire Capital shall not effect any sales under the purchase agreement on any purchase date where the closing sale price of common stock is less than $0.44 (the closing sale price of shares on the business day before the Company entered into the purchase agreement). Further, the purchase price for any purchases of shares under the purchase agreement may not be less than $0.44 per share, unless stockholder approval is obtained. The respective prices and share numbers in the preceding paragraphs shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction. There are no trading volume requirements or restrictions under the purchase agreement with Aspire Capital, and the Company will control the timing and amount of any sales of our common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed in accordance with the purchase agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the purchase agreement. The purchase agreement may be terminated by the Company at any time, at its discretion, without any penalty or cost to the Company"...
btv - affinor in a spot near the end...
re: "[...] UC Davis lab, [...] awarded $200,000 to ramp up production of the anti-Ebola drug ZMapp"
They got a grant but it doesn't say from whom.
So... maybe not from the gov.
It could be from a major biotech that needs to find a way to keep their presumably massive investment in bioreactors from becoming obsolete, and as a result, if not worthless, a lot less valuable along with loss of profits from their traditional use as the only game in town.
It looks like they (the benefactors) want to find a way to use (modified?) plant cell cultures instead of animal cells in bioreactors, even though that second generation tech method looks to be superceded by (ibio's) third generation tech which involves simply using unmodified whole plants (no bioreactors needed).
Just a theory here...
Good for the industry in general, but reduces the need for "fresh" uranium. US doesn't currently use it though.
http://www.heritage.org/research/commentary/2007/12/recycling-nuclear-fuel-the-french-do-it-why-cant-oui
I think that 0.44 is the floor price on the Aspire capital share purchase financing agreement. There is still some hangover from the bogus lawsuit announcements and accompanying misinformed hit pieces though they are fading from the financial media. Whatever die-heart short sellers remain will probably realize that they would be encumbered to cover as that point is approached. so, hopefully, move on to the next target.
came here to take a look . ticker was mentioned on another board.
if I am reading the recent financials right, it looks like they sold their oil wells and now also have debt.
so, nice business plan, but not so appealing as before...
Considering Tweed made over $300k their first month, and Supreme will have more time and a ready inventory when they are approved for sales, I wouldn't expect them to have any trouble making the payments.
Oh no! My coffee got cold!
WHAT A DISASTER! lol
Great article. Thanks for posting.
"...an investor and partnering conference ..."
That could definitely help the cause here.
I'm pretty sure they don't invite just anybody to these things.
($$$)
ZMapp is an experimental drug administered separately. The HP devices use the lectin (though it has a longer official name).
beep.... beep.... beep....
The seeds can also be popped to make tasty miniature popcorn. :)
The chart looks like a classic double top to me. The second peak is higher, and we're still up from pre-event levels. The intervening hump probably contains some short covering. Looks normal to me.
The big event, as I see it, was that, for the first time, news media reported that ebola was in the US for the first time and btw there's only one first time for anything. Somebody with big bucks, probably at a hedge fund, gave the word:" Go buy ebola stocks, Buy anything ebola!" The stock scans were run and the money poured out. That got the ball rolling. Now, lot's of momentum traders are always scanning for quick plays, so they all stated piling in simply based on technical chart action, probably with scarcely a second thought as to why all these stocks are moving up all of a sudden. Then feckless inexperianced traders get all giddy and start buying at the top, pushing it up even further. Finally, the cresendo. Prudent momentum traders start exitting. Short sellers have opened the taps on the way up, they're still open, it starts going down. The taps tend to stay open longer than necessary, shorts can get carried away just like longs. Late comers try to catch the falling knife, grab too soon, and end up underwater.
Obviously IBIO has more value now due to the ebola response but also the technology is being more seriously looked at in general. The company is actually in a legitimately good position.
But what portion of the peak was due to mindless buying frenzy as compared to increased "good will" factor (in the accounting sense)? Easy enough to find the stocks that shot up. One interesting specimen is Versa. The share price doubled on Oct. 13. They do mostly goverment contracting work, security related construction, some remediation. The word "ebola" is nowhere in their website. Oh, they have a few hazmat suits for toxic chemical site remediation, but that represents less than 2% of their business. It went up purely due to getting swept up in the mindless buying frenzy going on all around it.
So, basically, we need to take the $3.48 peak, subtract the normal pre-event pps of around 50 cents and divide by 2 which comes to about $1.50.
The "hype" factor for sh*t stocks being pumped by paid stock promoters and dingbat newletters is high and they have all come crashing down severely if not suspended by the SEC. On the other hand, IBIO didn't pump. They simply said what they were doing, they could help with ebola, which they can, and are. No exaggerated claims or unrealistic projections. So, very little pump factor. The true point of maximum optimism, near term, would seem to between $1.00 and $1.50. That's why I'm thinking, quite possible,back over a dollar, near term and then wandering up from there, long term.
Need to to wait for them to announce what they're up to, of course. Expect it to be in more of a matter-of-fact tone than a pump, though. - JMHO
It seems to work best in combination with ZMapp. One of the big drug co. is working on making more using CHO (Chinese Hampster Ovaries) but the best bet for large scale production is using tobacco plants which I believe is being done by Caliper using a process licensed from IBIO.
“The Stock Market is designed to transfer money from the Impatient to the Patient.”-- Warren Buffet
actually meant to post the following reply here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109586231
re: "...Big Tobacco is coming for you..."
It is kind of ominous sounding isn't it ...
Direct Competition? I don't see them starting from scratch. Possible but not likely...
Acquisitions? Likely that is the scenario being referred to. That could range from "friendly" (buying controlling interest at a premium - not too bad for shareholders if down the road). Or, "hostile" takeovers which could be bad depending on what it takes for Trudy Trueheart to give up the deed of the farm to Snidely Whiplash. (a little allegory there).
With those kinds of bucks, the capacity for manipulation is breathtaking. Hopefully it won't be like a certain big movie studio taking over a little one that occurred not too many years ago. They hired a hedge fund manager as vp, then a huge smear campaign erupted directed at what would have been a very successful movie. It was amazingly effective at getting the movie boycotted, revenues never materialized, then the stock tanked, presumably helped along into obliteration by short selling, after which the shares were scooped up at a small fraction of their former price and the absorption was complete. And nobody is the wiser. It's possible the article authors have seen similar things. Yup, with a worst case scenario it could get pretty nasty.
OTOH, There's probably quite a bit of time before that becomes an immediate concern for shareholders in the sector. And who knows, maybe tobacco companies are nicer. :)
Tax loss selling (of probably mostly oil and resource stocks) is over. Now people have extra cash in their accounts to re-invest in areas where growth is expected.
mj production could be thought of as a kind of resource so would have an obvious attraction to former conventional resource investors exiting that current bear market.
just a guess...
I think the frivolous lawsuits all evaporated on dec 23, the deadline for them to find a lead plaintiff which they never did as far as I know. So they never made it out of the gate.
hm. all the old neg "news releases" and "reminders" are still out there even though there is no case. But the law firms aren't going to announce failure are they.
Seems like somebody should announce something though...
to clear the air.